Trial Profile
A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 16 Nov 2020 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.
- 16 Nov 2020 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2022.